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Abstract
The Epithelial Cell Adhesion Molecule (EpCAM) is overexpressed in many cancers including ovarian cancer and EpCAM
overexpression correlates with decreased survival of patients. It was the aim of this study to achieve a targeted methylation
of the EpCAM promoter and silence EpCAM gene expression using an engineered zinc finger protein that specifically binds
the EpCAM promoter fused to the catalytic domain of the Dnmt3a DNA methyltransferase. We show that transient
transfection of this construct increased the methylation of the EpCAM promoter in SKOV3 cells from 4–8% in untreated cells
to 30%. Up to 48% methylation was observed in stable cell lines which express the chimeric methyltransferase. Control
experiments confirmed that the methylation was dependent on the fusion of the Zinc finger and the methyltransferase
domains and specific for the target region. The stable cell lines with methylated EpCAM promoter showed a 60–80%
reduction of EpCAM expression as determined at mRNA and protein level and exhibited a significantly reduced cell
proliferation. Our data indicate that targeted methylation of the EpCAM promoter could be an approach in the therapy of
EpCAM overexpressing cancers.
Citation: Nunna S, Reinhardt R, Ragozin S, Jeltsch A (2014) Targeted Methylation of the Epithelial Cell Adhesion Molecule (EpCAM) Promoter to Silence Its
Expression in Ovarian Cancer Cells. PLoS ONE 9(1): e87703. doi:10.1371/journal.pone.0087703
Editor: Jorg Tost, CEA - Institut de Genomique, France
Received October 29, 2013; Accepted January 1, 2014; Published January 29, 2014
Copyright:  2014 Nunna et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work has been supported by the Sander Foundation and the DAAD (Deutscher Akademischer Austauschdienst). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: albert.jeltsch@ibc.uni-stuttgart.de
Introduction
Cancer occurring in the peritoneal cavity of the ovaries is the
seventh most common cancer in women and second leading cause
of death worldwide among gynecological cancers [1–3]. In most
women, ovarian cancer is difficult to treat with a five year survival
rate of around 20% in cancers diagnosed in advanced stage [4–6].
Platinum-based analogues such as Cisplatin or Carboplatin are the
major standard chemotherapy agents to treat ovarian cancer in
initial stages [7]. However, their use is hindered by the acquired or
intrinsic resistance of the cancer cells to the drug [8]. In spite of an
increased understanding in the etiology of ovarian cancer there
has been little change in the survival of patients over the past 30
years, because in the early stages ovarian cancer is asymptomatic
and there are no efficient tumor specific and sensitive markers to
monitor epithelial ovarian cancer [9]. Thus, there is an immediate
need for new strategies for the treatment of ovarian cancer.
Ovarian cancer cells exhibit over expression of the Epithelial
Cell Adhesion Molecule (EpCAM) when compared with normal
ovarian cells [10–14]. EpCAM (NCBI Reference Sequence
NM_002354.2; also called GA733, KSA, 17-1A antigen, or
CD326) is a 40 kDa epithelial cell surface glycoprotein that
mediates Ca2+ independent homophilic cell-cell adhesion
[10,15,16]. The epithelium of healthy individuals expresses
EpCAM, with the exception of squamous epithelium and of
specific epithelial cells of adult hepatocytes and keratinocytes [17].
EpCAM is over-expressed to varying degrees in numerous human
carcinomas [18,19], cancer-initiating cells, and in progenitor and
normal stem cells [20]. It has recently been shown that EpCAM
upregulates c-myc, cyclin A and E and it influences the cell cycle and
enhances cell proliferation [21]. In addition, it is involved in the
nuclear Wnt-signaling pathway that also promotes cell prolifera-
tion and tumorigenesis [20].
Though the exact role of EpCAM is elusive in ovarian cancer
progression, the EpCAM over expression significantly correlates
with decreased survival rate in patients at stage III/IV of the
disease and over expression of EpCAM in breast and gallbladder
cancer has a strong correlation with poor prognosis [22–24]. Anti-
EpCAM antibodies were used to identify circulating tumor cells in
the blood of cancer patients, and to provide prognostic informa-
tion that allows treatment of patients [25]. In addition, the direct
association of EpCAM with the progression of ovarian cancer
suggested that it may serve as potential therapeutic target for the
treatment of ovarian cancer and different approaches have been
established to target EpCAM [26,27]. EpCAM antibodies such as
MT201 efficiently eliminate cancer cells from ovarian cancer
patients [28]. For example, Catumaxomab has been approved for
the treatment of malignant ascites and it has been used for
epithelial ovarian and non-ovarian cancers [29–31]. Although,
anti-EpCAM monoclonal antibodies provide protection against
cancer [32,33], the antibody dependent cytotoxicity relies on the
CH2 domain of the antibody that varies significantly from batch to
batch during antibody production [34]. In addition, anti-EpCAM
antibodies failed to provide any clinical protection against
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colorectal and prostate cancer due to the large size of the antibody
which confines distribution and delivery [34–36]. Hence, better
and more general strategies for the targeted repression of EpCAM
are required.
As an alternative approach, the oncogenic function of EpCAM
was inhibited by reducing the expression of its gene. One method
to achieve this was the application of antisense RNA which has led
to a strong decrease in cell proliferation and metabolism in human
carcinoma cells [21]. In a similar approach, siRNA mediated
silencing of EpCAM expression strongly reduced the cell
migration and invasive potential of breast cancer cells [23].
EpCAM expression was also silenced by the expression of a Zinc-
finger protein which binds to the EpCAM promoter [37] and a
fusion of an EpCAM targeting Zinc finger domain with a repressor
domain [38]. However, all these approaches did not lead to a
persistent down regulation which stimulated attempts to connect
gene repression with epigenetic marks, like DNA methylation.
DNA methylation plays an important role in epigenetic regulation
of gene expression [39–42]. In mammals, DNA methylation
occurs at C5 position of the cytosine mainly in the context of CpG
dinucleotides. The CpG rich regions are termed CpG islands and
often occur in gene promoter regions [43]. The EpCAM promoter
contains a CpG island, the methylation of which inversely
correlates with EpCAM expression, tumor invasion and progres-
sion in various cancer types [13,44]. In support of this concept, it
could be shown that DNA methylation introduced at the promoter
in an undirected fashion led to down regulation of the EpCAM
gene [45].
Clearly, to reduce side effects of an epigenetic gene silencing
treatment, a targeted delivery of silencing epigenetic marks like
DNA methylation is needed. This requires the coupling of a
catalytic moiety which delivers the silencing signal with a targeting
part, which ensures the specific binding of the catalytic entity to a
defined genomic target [46–48] (Fig. 1). Different molecular
entities are in use for the sequence specific targeting function,
including fusion of the DNA methyltransferase part to a triplex
forming oligonucleotide [49], fusion to engineered Zinc finger
proteins (see below), TAL effectors [50,51] and in future
potentially engineered CRISPR/CAS systems [52]. Since Zinc
fingers were the first protein modules for which design of sequence
specific DNA binding became possible [53–58], initial targeted
methylation studies relied on artificial zinc-finger proteins as
targeting device [59]. Following this approach, the repression of
viral genes [60], down-regulation of Maspin and SOX2 [61] and
the VEGFA gene suppression [62] has been achieved in human
cell lines. In this work, we fused a Zinc finger protein that targets
the EpCAM promoter [37] to the DNA methyltransferase 3a
(Dnmt3a) catalytic domain in order to methylate the EpCAM
promoter, which subsequently should lead to EpCAM silencing.
We used SKOV3 cells which are derived from human female
adenocarcinoma cells and have been used as a model for ovarian
cancer [45]. We show that the targeted methylation of the
promoter leads to reduction of the EpCAM gene expression,
further supporting the notion that targeted DNA methylation is a
general approach to gene silencing. Furthermore, we show that
silencing of EpCAM leads to a reduction in proliferation of
SKOV3 cells.
Materials and Methods
Cell culture, transfection and enrichment of transfection
SKOV3 human ovarian cancer cells were obtained from ATCC
(American type culture collection). The cells were cultured in
Dulbecco’s modified Eagle’s medium (PAA) supplemented with
10% fetal bovine serum and 2 mM L-glutamine (PAA). For
transient transfection, 3.56105 cells were seeded in T25 flasks and
the cells were transfected after one day with 12 ml of FuGENE HD
transfection reagent (Promega) and 6 mg of three plasmid DNAs
which express one the different Zinc finger fusion constructs used
in this work, the LNGFR marker, and GFP in a ratio of 10:2.5:1 as
previously described [62]. The transfected cells were enriched
using MACSelectTM LNGFR system (Miltenyi Biotec) according
to the manufacturer’s instructions. Briefly, when cells are co-
transfected with the LNGFR molecule, it is expressed on the cell
surface. After four days, cells were incubated with magnetic beads
conjugated with anti-LNGFR antibody for 15 minutes at 4uC.
Transfected cells were passed through a MACS separation column
placed in a MACS separator and washed twice with PBE buffer
(Phosphate buffer saline with 0.5% bovine serum albumin and
5 mM EDTA) to wash away the untransfected cells. After
washing, only transfected cells bound by magnetic beads are
retained in the column and the enriched cells were eluted in PBE
and used for further methylation analysis.
For stable cell line generation, 26105 cells were seeded per well
in 6 well plates, and the cells were transfected with 6 ml of
FuGENE HD transfection reagent and 2 mg of EpCAM ZF-
Dnmt3aCD plasmid DNA. After 48 h, the cells were grown in
medium containing 800 ng/ml G418 for six weeks. Monoclonal
colonies were obtained and further expanded in the presence of
G418 containing medium and two of the stable cell lines were used
for further experiments.
Methylation analysis of the EpCAM promoter and non-
target gene methylation
Genomic DNA was isolated using QIAampH DNA mini kit
(QIAGEN), and bisulfite conversion was carried out as described
previously [63]. Briefly 400 ng of genomic DNA was digested with
SphI restriction enzyme overnight at 37uC. Bisulfite conversion
was carried out in the presence of NaOH and sodium bisulfite
using the following conditions: 15 min incubation at 99uC, 30 min
at 50uC, 5 min at 99uC, 1.5 h at 50uC, 5 min at 99uC and 1.5 h at
50uC. During the incubation with bisulfite, unmethylated cytosine
is converted to uracil but methylated cytosines remain unchanged.
Afterwards, the DNA was concentrated and purified using Amicon
ultra centrifugal filters (Millipore) and PCR amplified using
bisulfite specific primers. The uracil is amplified as Thymine in
this reaction. The PCR product was subcloned using StrataClone
PCR cloning kit and individual clones were sequenced. To analyze
its methylation status, 220 bp of the EpCAM promoter containing
16 CpGs was amplified using specific primers (For: 59-CTT TTT
AAG GTT TTA GAG TAG-39 and Rev: 59-AAA AAA TAA
ATA AAC TCC CCT CCC-39). For non-target gene methylation,
four amplicons from genes (KIAA0179, DSCR3, Sumo3 and
WRB, respectively) were analyzed; the sequences of all amplicons
and a list of primers used are given in Supplementary Information
S1. Data were analyzed using the BISMA software [64].
RT qPCR analysis
Total RNA was isolated from stable cell lines and control
SKOV3 cells using PurelinkTM RNA mini kit (Ambion). A total of
1.0 mg RNA was converted into complementary DNA using M-
MuLV Reverse Transcriptase (NEB) with oligo dT primers. Q-RT
PCR was carried out using CFXConnectTM Real-Time system
(Bio-Rad). EpCAM transcript expression levels were quantified
using SsoFastTM EvaGreenH supermix (Bio-Rad) and EpCAM
specific primers (for: 59-GAACAATGATGGGCTTTATG-39,
rev: 59-TGAGAATTCAGGTGCTTTTT-39) using beta actin as
internal control (for: 59-TCACCAACTGGGACGACATG-39,
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rev: 59-ACCGGAGTCCATCACGATG-39). The relative amount
of transcript was measured by threshold cycle amplification (CT)
which is inversely correlated with the amount of RNA present.
The fold change in EpCAM RNA was calculated using the DDCt
method. Ct values are determined as mean of triplicates and the
experiment was carried in two technical repeats.
Western blotting
Cell lysates were prepared from stable cell lines and control
SKOV3 cells using RIPA buffer (50 mM Tris, 150 mM NaCl,
1%NP40 and 1 mM PMSF), and the total protein content was
quantified by BCATM Protein assay kit (Thermo Scientific).
Four mg of total protein was resolved on 10% SDS-PAGE gels and
transferred to a nitrocellulose membrane. The membrane was
blocked overnight by incubation with 4% bovine serum albumin
in Phosphate buffer saline, and probed with rabbit anti-human
EpCAM IgG in 1:4000 dilution (Abcam Ab71916), followed by
horseradish peroxidase conjugated goat anti-rabbit IgG in 1:4000
dilution (GE Healthcare). The blots were developed using
enhanced chemiluminescence western blotting solution (Thermo
Scientific), and images were captured on X-ray films, scanned, and
quantified using Image J software.
Cell Proliferation assay (CCK8 assay)
Cell proliferation assays were performed using Cell counting kit-
8 (CCK8) assay (Dojindo) according to the manufacturer’s
instructions. Briefly, SKOV3 cells or stable cell lines CD1 and
CD2 were seeded in a density of 1.56104 cells in 200 ml medium
in a 96 well cell culture plate and grown for three days in DMEM
with 10% FCS at 37uC with 5% CO2. After three days, the
cells were treated with 10 ml of the CCK8 reagent per well
and incubated for 4 h in the CO2 incubator. Then, 100 ml
supernatant from each well were transferred into fresh 96
well plates and the absorbance was measured at 450 nm using
spectrophotometer. The CCK8 reagent contains WST-8
[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-
2H-tetrazolium, monosodium salt] dissolved in water and cell
culture medium, which can enter the cell where it is reduced by
Figure 1. Principle of targeted DNAmethylation and gene silencing using Zinc fingers (ZF) fused to the catalytic domain of the DNA
methyltransferase Dnmt3a (Dnmt3aCD). The blue bar represents the ZF binding site, unfilled lollipops represent unmethylated CpGs and filled
lollipops represent methylated CpGs.
doi:10.1371/journal.pone.0087703.g001
Figure 2. Genome context of the EpCAM gene (indicated by a blue bar) on chromosome 2 p21. The gene is shown in blue, its CpG island
in green and the amplicon in black. The amplicon sequence is given below, the ZF binding site sequence is shaded in red. This picture was generated
using University of California Santa Cruz genome browser (http://genome.ucsc.edu/) [66].
doi:10.1371/journal.pone.0087703.g002
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dehydrogenases to give an orange colored formazan product.
The amount of formazan formed is directly proportional to the
number of living cells.
Cell counting assay
SKOV3 cells or stable cell lines CD1 and CD2 were seeded in a
six well cell culture plate in a density of 26105cells per well and
cultured for four days in DMEM with 10% FCS at 37uC with 5%
CO2. After four days, the cells were washed twice with Phosphate
buffer saline, trypsinized and harvested separately and a single cell
suspension was prepared. Cells were diluted in Trypan blue stain
0.4% (Gibco) in a ratio of 1:1 and the total number of viable cells
in each well was counted using a Neubauer counting chamber or
haemocytometer. Live cells can be differentiated from dead cells,
because dead cells take up the dye and stain dark blue whereas the
membranes of living cells are intact and prevent the uptake of the
dye.
Results
Targeted DNA methylation of EpCAM promoter in
ovarian cancer SKOV3 cells
It was the aim of this study to achieve a targeted methylation of
the EpCAM promoter and silence EpCAM gene expression. We
have used an engineered zinc finger protein that specifically binds
the EpCAM promoter [37] and fused it with the catalytic domain
of the Dnmt3a DNA methyltransferase (Dnmt3aCD), which
previously has been successfully used to introduce targeted DNA
methylation [60,62]. For the target specific methylation, SKOV3
cancer cells, which have an unmethylated EpCAM promoter and
active EpCAM expression [11], were transiently transfected with
the chimeric Zinc finger - Dnmt3a catalytic domain (ZF-
Dnmt3aCD) constructs. After four days the transfected cells were
enriched by MACS selection and the methylation status of the
EpCAM promoter (Fig. 2) was analyzed by bisulfite conversion
and sequencing of individual clones. In two independent
experiments, untransfected SKOV3 cells showed a basal level of
4–8%DNA methylation. However, the methylation increased to
29% (64%) in ZF-Dnmt3aCD transfected cells in two indepen-
dent experiments (Fig. 3). Importantly, our data show that
methylation levels of .80% could be achieved at some specific
CpG sites of the target region, like the sites 14–16. The EpCAM
promoter showed basal level of methylation in SKOV3 cells that
were transfected with control vectors, either vector control alone,
zinc finger without Dnmt3aCD or Dnmt3aCD without zinc
finger, respectively (Fig. 3). The finding that the expression of
untargeted Dnmt3a catalytic domain did not lead to a large
increase in DNA methylation at the EpCAM promoter is in
agreement with previous observations at another target locus [62].
Since we conducted the methylation experiments in transiently
transfected cells after MACS selection, a background of untrans-
fected cells was still present, which we estimate to be in the range
of 20% based on microscopic observation. To obtain a homog-
enous cell sample, in which all cells were treated with the chimeric
methyltransferase, we generated two independent stable cell lines
(called CD1 and CD2), which express the Zinc finger Dnmt3aCD
chimeric methyltransferase. Genomic DNA was isolated from both
cell lines and the methylation status of the EpCAM promoter was
analyzed as described above. Our results show that the methyl-
ation levels of EpCAM promoter were increased to 46% in the
stable cell line CD1 and 48% in CD2 (Fig. 3).
Figure 3. Examples of the results of the DNA methylation analysis of the EpCAM gene promoter in SKOV3 cells. The following
abbreviations were used: SKOV3 cells, untreated cells; ZF, SKOV3 cells transfected with Zinc finger construct, ZF-Dnmt3aCD, cells transfected with the
Zinc finger Dnmt3a catalytic domain construct; VEC cntrl, cells transfected with empty vector; Dnmt3aCD, cells transfected with a Dnmt3aCD
construct without Zinc finger; CD1, stable cell line expressing ZF-Dnmt3aCD 1; CD2, stable cell line expressing ZF-Dnmt3aCD 2. The horizontal rows
indicate the CpGs in the amplicon analyzed and the vertical rows represent individual clones that were sequenced. The blue and red colors represent
unmethylated CpG and methylated CpG, respectively, for white colored sites, the methylation state is unknown due to technical reasons.
doi:10.1371/journal.pone.0087703.g003
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Off-target gene methylation
To analyze methylation at other loci that may accompany our
targeted methylation, we investigated the methylation status of four
additional non-target genes (KIAA0179, DSCR3, Sumo3 and
WRB) as described in the materials and methods. The SKOV3 cells
showed a methylation of 1%, 1%, 17%, and 2% respectively, in the
four amplicons (Fig. 4 and [62]). SKOV3 cells transiently
transfected with ZF-Dnmt3aCD showed methylation levels of 1%,
1%, 22%, and 1% which are almost identical to the results obtained
with the untreated SKOV3 cells (Fig, 4). The stable cell lines CD1
and CD2 also showed methylation patterns very similar to the
control cells (Fig, 4). While these results do not rule out additional
methylation occurring at some individual loci, they show that the
methylation of the EpCAM promoter is not accompanied by a
massive, unspecific and genome-wide DNA methylation, indicating
that targeting was at least partially successful.
EpCAM expression is repressed by targeted DNA
methylation of EpCAM gene promoter
To determine if the promoter methylation led to transcriptional
silencing of the EpCAM gene expression, total RNA was isolated
from the SKOV3 cells and the stable cell lines CD1 and CD2 and
the EpCAM mRNA levels were determined by quantitative RT-
PCR. As shown in Fig. 5A and B, we observed a reduction of
EpCAM expression of 80% in stable cell line CD1 and 60% in
stable cell line CD2. The EpCAM suppression by targeted DNA
methylation was confirmed at the protein level by western blotting,
where we observed a corresponding reduction of EpCAM
expression in the stable cell lines compared to SKOV3 cells
(Fig. 5C and D).
Decreased EpCAM expression associates with a reduction
of cell proliferation
To investigate whether the reduced EpCAM expression affected
the proliferation of SKOV3 cells, an equal number of untreated
cells as well as CD1 and CD2 cells were seeded and a cell
proliferation assay was performed after three days. For this, the
cells were treated with the CCK8 reagent dissolved in cell culture
medium and incubated for 4 hours in the incubator. During this
time, the reagent can diffuse into the cells, where it is reduced by
cellular dehydrogenases to produce an orange colored formazan
product, which can be detected by absorption at 450 nm. Since
Figure 4. Absence of off-target methylation in SKOV3 cells analyzed by bisulfite sequencing. Methylation of four non-target genes was
analyzed (KIAA0179, DSCR3, Sumo3 and WRB). Data presentation is as in Fig. 3. The sequences of the regions analyzed here are given in the
Supplementary Information S1.
doi:10.1371/journal.pone.0087703.g004
Targeted Methylation and Silencing of EpCAM
PLOS ONE | www.plosone.org 5 January 2014 | Volume 9 | Issue 1 | e87703
the amount of the formazan is directly proportional to the number
of living cells, this assay allows an easy estimate of the number of
live cells in the sample. As shown in Fig. 6A, there was 60%
reduction of live cells in CD1 and 40% in CD2 when compared to
SKOV3 cell control, which is in a very good correlation with the
reduction of EpCAM expression in both cell lines. To confirm
these results, we also conducted viable cell counting using Trypan
blue, as described in materials and methods. For this an equal
Figure 5. Analysis of EpCAM gene expression after targeted promoter methylation in stable cell lines. A) Example of the RT qPCR
analysis of EpCAM (left) and beta actin (right) mRNA amounts in SKOV3 cells and in two independent cell lines which stably express the ZF-Dnmt3a
construct (CD1 and CD2). B) Quantification of the RT qPCR analysis of EpCAM expression as shown in panel A. We carried out two independent RNA
preparations each analyzed in three technical repeats. The image shows the average of both results, the error bars indicate the standard error. C)
Example of the Western blot analysis of EpCAM expression in SKOV3 cells and the CD1 and CD2 stable cell lines (upper panel). Beta actin was used as
loading control (lower panel). The EpCAM and beta actin bands are marked with arrows. D) Quantification of the Western Blot analysis of EpCAM
expression as shown in panel C. The figure shows an average of two independent experiments, the error bars indicate the standard deviation of the
data.
doi:10.1371/journal.pone.0087703.g005
Figure 6. Down regulation of EpCAM expression inhibits the proliferation of SKOV3 cells. A) Results of CCK8 cell proliferation assays
conducted with the CD1 and CD2 stable cell lines and SKOV3 cells as reference. The results plotted are from four independent experiments and the
error bars indicate the standard error of the mean. B) Viable cell counting performed by Trypan blue staining. The graph represents the data from two
independent experiments and the error bars indicate the standard error of the mean.
doi:10.1371/journal.pone.0087703.g006
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number of cells were seeded and incubated for four days.
Afterwards, the total number of viable cells were counted. As
shown in the Fig. 6B, the results corroborated the cell proliferation
assay, because there was an about 50% reduction in the number of
live cells in CD1 and about 40% in CD2. We conclude that the
down regulation of EpCAM leads to a significant reduction of the
proliferative potential of SKOV3 cell in vitro.
Discussion
Targeted DNA methylation by fusion of a DNA methyltrans-
ferase domain (here the catalytic domain of Dnmt3a) and a
targeting device (here a designed Zinc finger) is an attractive
approach for gene silencing [46–48]. There are some previous
examples of the successful application of this method to achieve
gene silencing in human cells [60–62]. Here, we demonstrate the
targeted methylation and gene silencing of the EpCAM gene,
which is a promising target in tumor therapy. We show absence of
off-target effects at all loci that were inspected for this, which
indicates that targeting was (at least partially) successful. Our
results support the notion, that targeted methylation and gene
silencing is a universal approach with broad applicability.
Furthermore, we demonstrate that the silencing of EpCAM
expression leads to a reduction in the proliferative potential of
SKOV3 cells.
In a recent paper, der Gun et al. (2013) reported an about
twofold silencing of EpCAM after the expression of a Zinc finger
fused repressor Kruppel-associated box (SKD) domain, which was
delivered with a retroviral vector [38]. Interestingly, this led to a
reduction of proliferation in breast cancer cells, but not in SKOV3
cells. Similarly, an RNAi based silencing of EpCAM in SKOV3
cells did not reduce cell proliferation in this work. These results
with SKOV3 cells are not in agreement with our data, but there
are important differences in the setup of both studies. First of all,
van der Gun et al. (2013) used a repression domain, while we
employed a DNA methylation mediated epigenetic silencing
mechanism. In fact, EpCAM silencing was slightly stronger in
our setup, 60–80% in our cell lines vs. 50% observed by van der
Gun et al. (2013), which may influence the results. Second, van der
Gun et al. (2013) delivered their silencing construct with retroviral
vectors and use empty vectors as control. Cell proliferation was
assayed 4–6 days after transduction. Our study employed cell lines
which express the silencing constructs in a stable manner after an
initial transient transfection. Both methods have their advantages
and disadvantages. In the retroviral delivery, cellular effects are
measured few days after a retroviral infection, which may strongly
affect the cellular responses. In addition, in the stable cell line,
EpCAM was silenced for several weeks before the cell proliferation
analysis was conducted, which gave the cell long time to respond
to the reduction of EpCAM expression. In contrast, the
proliferation tests of van der Gun et al. (2013) were performed 4
to 6 days after transduction and in the RNAi experiments the
readout was done 1 to 3 days after siRNA transfection, which may
be another reason for the difference in results. It is one
disadvantage of the stable cell line approach that individual cell
lines are studied which may have accumulated special adaptations.
However, the fact that both stable lines studied here showed
similar effects, partially addresses this concern. We conclude that
further experiments will be needed to resolve this issue, but the
reduction of the proliferative potential of a tumor cell line
observed here after epigenetic silencing of the EpCAM promoter is
a promising result for potential therapeutic applications of
EpCAM silencing in the treatment of cancers with EpCAM
overexpression.
For future applications of targeted gene silencing, the efficiency
of the delivery of the targeted methyltransferase construct must be
improved; several viral delivery strategies are available to this end
and are currently developed in our lab and at other places [61,65].
After the development of several active and functional chimeric
methyltransferases that work in cell culture models, it will be one
next critical milestone of the future work to integrate these
enzymes into an efficient delivery system that allows infection of
tumor cells in the animal (or human) body, and leads to inhibition
of tumor development in animal models. If this can be achieved, it
will also be necessary to determine the potential off-target
methylation on a genome wide scale and in a quantitative manner
in different tissues. For this, several genome wide DNA
methylation analysis methods are available. Depending on the
amount of off-target methylation and the affected loci, a risk
analysis will allow to assess if these reagents could be safe for
clinical trials. If needed the specificity of targeting could be
improved by using Zinc fingers modules which recognize longer
sequences than used here. Eventually other targeting methods, like
TAL effector domains or CRISPR derived methods may be
employed, although for them specificity is an issue as well.
Supporting Information
Information S1 Primer and amplicon sequences.
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